Company: SNWV
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001628280-25-023881
Chunk: 25

Company: SANUWAVE Health, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 25
---
,901 2,501 Amortization of debt issuance and debt discounts530 1,553 Accrued interest and accrued interest, related party- 955 Changes in operating assets and liabilitiesAccounts receivable(570)152 Inventory(1,308)490 Prepaid expenses and other assets(325)192 Accounts payable423 (643)Accrued expenses and contract liabilities(774)(42)Net Cash Flows (Used in) Provided by Operating Activities(1,517)1,100 Cash Flows - Investing ActivitiesPurchase of property and equipment(162)(114)Net Cash Flows Used in Investing Activities(162)(114)Cash Flows - Financing ActivitiesProceeds from factoring, net- 71 Payments of principal on finance leases(57)(29)Net Cash Flows (Used in) Provided by Financing Activities(57)42 Effect of Exchange Rates on Cash- 111 Net Change in Cash During Period(1,736)1,139 Cash at Beginning of Period10,237 1,797 Cash at End of Period$8,501 $2,936 Supplemental Information:Cash paid for interest$1,118 $971 Non-cash Investing and Financing Activities:Capitalize interest into senior secured debt202 - Stock options granted in lieu of cash bonus117 - Leased assets obtained in exchange for lease liabilities430 - Warrants issued in conjunction with convertible promissory notes - 2,784 Conversion of asset-backed secured promissory notes to convertible promissory notes- 4,584 

The accompanying notes to condensed consolidated financial statements are an integral part of these financial statements.

7

SANUWAVE HEALTH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2025

1.        Nature of the Business and Basis of Presentation

SANUWAVE Health, Inc. and subsidiaries (“SANUWAVE” or the “Company”) is focused on the commercialization of its patented regenerative medicine utilizing noninvasive ultrasound or shockwaves to produce a biological response promoting the repair and regeneration of tissue, musculoskeletal, and vascular structures.Basis of Presentation - The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for